Literature DB >> 11141092

Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.

J P Falgueyret1, R M Oballa, O Okamoto, G Wesolowski, Y Aubin, R M Rydzewski, P Prasit, D Riendeau, S B Rodan, M D Percival.   

Abstract

Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found to be a potent inhibitor of cathepsins K and L with a K(i) value of 50 nM for cathepsin K. Replacement of the 1-cyanopyrrolidine of compound 2 by a 1-cyanoazetidine increased the potency of the inhibitor by 10-fold. This increase in potency is probably due to an enhanced chemical reactivity of the compound toward the thiolate of the active site of the enzyme. This is demonstrated when the assay is performed in the presence of glutathione at pH 7.0 which favors the formation of a GSH thiolate anion. Under these assay conditions, there is a loss of potency in the 1-cyanoazetidine series due to the formation of an inactive complex between the GSH thiolate and the 1-cyanoazetidine inhibitors. 1-Cyanopyrrolidinyl inhibitors exhibited time-dependent inhibition which allowed us to determine the association and dissociation rate constants with human cathepsin K. The kinetic data obtained showed that the increase of potency observed between different 1-cyanopyrrolidinyl inhibitors is due to an increase of k(on) values and that the association of the compound with the enzyme fits an apparent one-step mechanism. (13)C NMR experiments performed with the enzyme papain showed that compound 2 forms a covalent isothiourea ester adduct with the enzyme. As predicted by the kinetic analysis, the addition of the irreversible inhibitor E64 to the enzyme-cyanopyrrolidinyl complex totally abolished the signal of the isothiourea bond as observed by (13)C NMR, thereby demonstrating that the formation of the covalent bond with the active site cysteine residue is reversible. Finally, compound 2 inhibits bone resorption in an in vitro assay involving rabbit osteoclasts and bovine bone with an IC(50) value of 0.7 M. 1-Cyanopyrrolidine represents a new class of nonpeptidic compounds that inhibit cathepsin K and L activity and proteolysis of bone collagen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11141092     DOI: 10.1021/jm0003440

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype.

Authors:  Michael C Myers; Parag P Shah; Mary Pat Beavers; Andrew D Napper; Scott L Diamond; Amos B Smith; Donna M Huryn
Journal:  Bioorg Med Chem Lett       Date:  2008-05-01       Impact factor: 2.823

2.  Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide.

Authors:  Yun Wang; Arthur F Monzingo; Shougang Hu; Tera H Schaller; Jon D Robertus; Walter Fast
Journal:  Biochemistry       Date:  2009-09-15       Impact factor: 3.162

3.  Discovery of novel cyanamide-based inhibitors of cathepsin C.

Authors:  Dramane Lainé; Michael Palovich; Brent McCleland; Emilie Petitjean; Isabelle Delhom; Haibo Xie; Jianghe Deng; Guoliang Lin; Roderick Davis; Anais Jolit; Neysa Nevins; Baoguang Zhao; Jim Villa; Jessica Schneck; Patrick McDevitt; Robert Midgett; Casey Kmett; Sandra Umbrecht; Brian Peck; Alicia Bacon Davis; David Bettoun
Journal:  ACS Med Chem Lett       Date:  2010-11-10       Impact factor: 4.345

4.  Structure reassignment and synthesis of Jenamidines A1/A2, synthesis of (+)-NP25302, and formal synthesis of SB-311009 analogues.

Authors:  Jeremy R Duvall; Fanghui Wu; Barry B Snider
Journal:  J Org Chem       Date:  2006-10-27       Impact factor: 4.354

5.  Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.

Authors:  Erica N Parker; Jiangli Song; G D Kishore Kumar; Samuel O Odutola; Gustavo E Chavarria; Amanda K Charlton-Sevcik; Tracy E Strecker; Ashleigh L Barnes; Dhivya R Sudhan; Thomas R Wittenborn; Dietmar W Siemann; Michael R Horsman; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2015-09-25       Impact factor: 3.641

6.  Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood.

Authors:  Mette Grøndahl Sørensen; Kim Henriksen; Sophie Schaller; Dennis Bang Henriksen; Finn Cilius Nielsen; Morten Hanefeld Dziegiel; Morten Asser Karsdal
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

7.  Synthesis and biochemical evaluation of thiochromanone thiosemicarbazone analogues as inhibitors of cathepsin L.

Authors:  Jiangli Song; Lindsay M Jones; G D Kishore Kumar; Elizabeth S Conner; Liela Bayeh; Gustavo E Chavarria; Amanda K Charlton-Sevcik; Shen-En Chen; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  ACS Med Chem Lett       Date:  2012-04-18       Impact factor: 4.345

8.  A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety.

Authors:  Matthew B Boxer; Amy M Quinn; Min Shen; Ajit Jadhav; William Leister; Anton Simeonov; Douglas S Auld; Craig J Thomas
Journal:  ChemMedChem       Date:  2010-05-03       Impact factor: 3.466

9.  Mechanistic insights into mode of action of novel natural cathepsin L inhibitors.

Authors:  Chetna Tyagi; Sonam Grover; Jaspreet Dhanjal; Sukriti Goyal; Manisha Goyal; Abhinav Grover
Journal:  BMC Genomics       Date:  2013-12-09       Impact factor: 3.969

10.  Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits.

Authors:  Brenda L Pennypacker; Renata M Oballa; Sonia Levesque; Donald B Kimmel; Le T Duong
Journal:  BMC Musculoskelet Disord       Date:  2013-12-09       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.